We are proud to present our final data of our study looking at benefit of vagus nerve stimulation in COVID-19 hospitalized patients performed in Buenos Aires, Argentina.
While the data has not been officially accepted for peer-reviewed publication yet, I felt it was important to release this data while the slow wheels of academia decide whether and when to publish.
We discovered that the use of transcutaneous VNS for 5 minutes, 4 times per day resulted in dramatically low rates of mechanical ventilation and survival rates almost as high as any other reported study.
COVID-19 is still a very real threat especially considering the almost weekly identification of escape mutations, some of which may be able to readily re-infect those with past COVID-19 infection. Fortunately, present vaccines still seem to be providing protection against infection. While not readily promoted in the U.S., transcutaneous vagus nerve stimulation offers a safe and potentially effective therapeutic option for other healthcare systems around the world struggling to care for their citizens.
